



Case Report

Vision improvement after trans-sphenoidal resection of pituitary macroadenoma

Sumit Prinja^{1,*}, Varun Aggarwal², Ramandeep Singh¹, Bhumika Trivedi¹, Dipesh¹

¹Dept. of ENT, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India

²Dept. of Neurosurgery, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India



ARTICLE INFO

Article history:

Received 21-03-2021

Accepted 25-03-2021

Available online 21-04-2021

Keywords:

Pituitary macroadenoma

Vision loss

TransSphenoidal resection

ABSTRACT

Introduction: Pituitary adenomas are tumours that occur in the Pituitary gland. Depending on the size it can be divided into Microadenoma (<10mm) and Macroadenoma(>10mm). It can present with endocrine manifestations secondary to hypo or hyper function of pituitary gland and ophthalmological manifestations due to mass effect.

Case Report: A 36-year-old female was admitted to our institution with complaints of loss of vision of right eye, headache and amenorrhea for 3 months, which were progressive in nature. Her MRI Scan revealed a well-defined sellar mass, measuring 27 x 23.18 mm, with suprasellar extension, causing expansion of pituitary fossa and superiorly extending into Hypothalamus with mild compression over optic chiasma. Prolactin level was 72.16 ng/ml. Surgery was done under general anesthetics, by Endoscopic assisted trans-sphenoidal approach. The adenoma was completely removed. Sella opening was closed by synthetic graft. On awakening from anesthetics visual acuity in right eye was immediately and completely restored.

Conclusion: Pituitary adenoma is a complex set of benign tumours that present with hypersecretory syndrome and mass effect. An appropriate imaging of pituitary region using MRI and endocrinological consultation is the standard for detection of pituitary adenoma. Although, medical management and radiotherapy offer effective treatment for these tumours in specific situations, Endoscopic Trans-sphenoidal approach continues to provide optimal outcomes with low incidence of morbidity.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Pituitary adenomas are tumors that occur in Pituitary gland. Pituitary adenomas are generally divided into three categories depending upon their biological function – Benign adenoma, Invasive adenoma, and Carcinomas. Mostly adenomas are benign, approximately 35% are invasive and just 0.1 to 0.2 % are carcinomas.¹ Pituitary adenomas comprise 10-15% of intracranial neoplasm and the estimated prevalence rate is 17%.^{2,3} Approximately 1 in 1000 people develops Pituitary adenoma. Pituitary adenomas are common in sellar area. Micro-adenomas are tumors measuring less than 10 mm in diameter and those of more than 10 mm are termed macro-

adenomas. Pituitary adenomas are present with endocrine manifestations secondary to hypo or hyper function of pituitary gland and ophthalmological manifestations due to mass effect. When the tumor grows beyond the confines of sella turcica, it commonly affects visual pathway and visual field deficit are present. Symptoms depend on the presence of Pituitary hypersecretion, absence or reduced hormonal level, destruction of normal Pituitary gland.^{4,5}

Pituitary adenomas are usually diagnosed by radiographic examination, history & blood testing for hormonal level.

Here, we present the case of patient with Pituitary macroadenoma with loss of vision, headache and amenorrhea.

* Corresponding author.

E-mail address: prinja2001@yahoo.com (S. Prinja).

2. Case Report

A 36-year-old female was admitted to our institution with complaints of loss of vision of right eye, headache and amenorrhea for 3 months. Symptoms were progressive in nature. General and systemic examination was found to be normal. Her MRI Scan revealed a well-defined sellar mass, measuring 27 x 23.18 mm, with suprasellar extension, causing expansion of pituitary fossa and superiorly extending into Hypothalamus with mild compression over optic chiasma. Her prolactin level was 72.16 ng/ml. Initial diagnosis was pituitary adenoma. Surgery was done under general anesthesia, by Endoscopic assisted Transsphenoidal approach. The adenoma was completely removed. Sella opening was closed by synthetic graft. On awakening from anesthesia visual acuity in right eye was immediately and completely restored. There was some CSF leakage during the surgery that was dealt with at the time. On first post-operative day visual acuity was checked and was found 5/6. Intravenous antibiotics and anti-inflammatory drugs were given for 7 days then patient was discharged.



Fig. 1: Pre-operative Contrast-enhanced CT scan of brain showing Pituitary Macroadenoma

3. Discussion

The Pituitary gland is about 2 to 8 mm in size and weight about 0.5 g. It is located within the sella turcica of sphenoid bone at the base of skull & covered by dural fold. Various important structures are present around Pituitary gland. The cavernous sinus and internal carotid artery are present on either side of it. The optic chiasma lies about 10 mm above it. The pituitary gland has two lobes. Anterior lobe secretes seven hormones like TSH, ACTH, GH, FSH, LH & Prolactin. Posterior lobe secretes two hormones-




Fig. 2: (A) Bilateral sphenoidotomy; (B) Drilling inter sphenoid septum; (C) Incision of duramater; (D) Complete removal of Pituitary Macroadenoma; (E) Closure of defect with HADAD flap

Vasopressin and Oxytocin. Pierre Marie was the first to describe a disease that involved the pituitary gland.^{6,7}

Pituitary tumors comprise 10-15% of intracranial neoplasm. Pituitary tumors can be classified on the basis of size. Macro-adenomas are more than 10 mm in diameter and micro-adenomas are less than 10mm in diameter. The tumor can also be classified as Chromo phobic, Acidophilic and Basophilic, depending upon the basis of histological staining. The tumors can also be divided on the basis of immune-histochemical staining & by serum hormone level, into secreting and non-secreting. The secreting tumors constitute 75% of pituitary adenoma.^{8,9} They include:

1. PRL cell adenoma
2. Growth hormone
3. Mix GH & PRL adenoma
4. Thyrotropin releasing hormone cell adenoma
5. ACTH cell adenoma
6. LSH & FSH cell adenoma

Prolactinomas comprise 40-50% of all pituitary adenoma. Prolactinomas generally occur in reproductive aged females and manifest with amenorrhea, galactorrhea. In males, it presents with gynecomastia, testicular atrophy, reduced body hair and impotence.¹⁰ Pituitary adenomas can also present with sudden onset of headache and loss of vision due to hemorrhage and necrosis of tumor as pituitary

apoplexy.¹¹

Diagnosis of pituitary adenomas is based upon radiological imaging (CT and MRI) and measurement of serum hormone level. They can be hyperdense or isodense compared with adjacent brain tissue and can show homogenous contrast enhancement with contrast material.¹²

Differential diagnosis includes olfactory neuroblastoma, Germinoma, Rhabdomyosarcoma.¹³

Pituitary adenomas can be treated by medical therapy, surgery and radiation therapy depending upon size, sign and symptom.

4. Conclusion

Pituitary adenoma is a complex set of benign tumors that present with hypersecretory syndrome and mass effect. An appropriate imaging of pituitary region using MRI and endocrinologic consultation is the standard for detection of pituitary adenoma. Although, medical management and radiotherapy offer effective treatment for these tumors in specific situations, Endoscopic Trans-sphenoidal approach continues to provide optimal outcomes with low incidence of morbidity.

5. Conflicts of Interest

All contributing authors declare no conflicts of interest.

6. Source of Funding

None.

References

- Basari R, Srivastava VK, Vasenwala SM, Ansari H. Pituitary adenoma: A case report with special emphasis on approach to diagnosis. *Clin Cancer Investig J*. 2014;3:264–7. doi:10.4103/2278-0513.132129.
- Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas. *Cancer*. 2004;101(3):613–9. doi:10.1002/cncr.20412.
- Costello RT. Subclinical adenoma of pituitary gland. *Am J Pathol*. 1936;12:205–16.
- Raju KV, Ruby MV. Pituitary macroadenoma: A case presentation. *Kerala J Ophthalmol*. 2006;18:58–60.
- Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. *Endocrine Relat Cancer*. 2001;8:287–305. doi:10.1677/erc.0.0080287.
- Kovacs K, Horvath E. Pathology of Pituitary Tumors. *Endocrinol Metabol Clin North Am*. 1987;16(3):529–51. doi:10.1016/s0889-8529(18)30463-8.
- Riskind PN, Richardson EP. Clinicopathologic conference-SN. *N Engl J Med*. 1986;314:229.
- Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. *Acta Neuropathol*. 2017;134(4):521–95. doi:10.1007/s00401-017-1769-8.
- Seltzer J. Outcomes following transsphenoidal surgical management of incidental pituitary adenomas: a series of 52 patients over a 17-year period. *J Neurosurg*. 2019;130:158–1592.
- Molitch ME. Diagnosis and Treatment of Pituitary Adenomas. *JAMA*. 2017;317(5):516. doi:10.1001/jama.2016.19699.
- Nawar RN, AbdelMannan D, Selman WR, Arafah BM. Analytic Review: Pituitary Tumor Apoplexy: A Review. *J Intensive Care Med*. 2008;23(2):75–90. doi:10.1177/0885066607312992.
- Jane JA, Michael MP, Laws ER. Surgical Treatment of Pituitary Adenomas. 2019;.
- Levy MJ, Matharu MS, Goadsby PJ. Prolactinomas, dopamine agonists and headache: two case reports. *Eur J Neurol*. 2003;10(2):169–73. doi:10.1046/j.1468-1331.2003.00549.x.

Author biography

Sumit Prinja, Associate Professor

Varun Aggarwal, Assistant Professor

Ramandeep Singh, Junior Resident

Bhumika Trivedi, Junior Resident

Dipesh, Junior Resident,

Cite this article: Prinja S, Aggarwal V, Singh R, Trivedi B, Dipesh. Vision improvement after trans-sphenoidal resection of pituitary macroadenoma. *IP Indian J Anat Surg Head, Neck Brain* 2021;7(1):39-41.